1355612-71-3
1355612-71-3
Chemical Structure
Caficrestat
Synonym(s): AT-001; Aldose reductase-IN-1
- CAS No.: 1355612-71-3
- Formula:C17H10F3N5O3S
- Molecular Weight:421.35
IUPAC Name: 2-(8-oxo-7-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-7,8-dihydropyrazino[2,3-d]pyridazin-5-yl)acetic acid
InChIKey: YRGPAXAVTDMKDK-UHFFFAOYSA-N
SMILES: O=C1C2=NC=CN=C2C(CC(O)=O)=NN1CC3=NC4=C(C=CC(C(F)(F)F)=C4)S3
Biological Activity: Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Caficrestat | 99.74% | Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yepuri G, Kancharla K, Perfetti R, Shendelman S, Wasmuth A, Ramasamy R. The aldose reductase inhibitors AT-001, AT-003 and AT-007 attenuate human keratinocyte senescence. Front Aging. 2024 Dec 17;5:1466281. [Content Brief]
- [2]. Gopal K, et ak. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol. 2023 Mar 28;22(1):73. [Content Brief]
